Change from baseline in key efficacy parameters at Week 12 by CRP subgroup (mean (SE))
| DARWIN 1 | DARWIN 2 | |||||
|---|---|---|---|---|---|---|
| PBO | filgotinib 100mg QD | filgotinib 200mg QD | PBO | filgotinib 100mg QD | filgotinib 200mg QD | |
| Low CRP subgroup (≤9 mg/L) | ||||||
| N | 33 | 25 | 15 | 11 | 20 | 20 |
| DAS28(CRP) | -1.2 (0.30) | -2.2 (0.24) | -2.2 (0.32) | -0.9 (0.55) | -2.1 (0.33) | -2.3 (0.25) |
| CDAI | -18.3 (3.52) | -23.7 (2.66) | -25.1 (3.45) | -11.5 (6.19) | -25.8 (3.53) | -27.4 (3.05) |
| HAQ-DI | -0.21 (0.121) | -0.76 (0.133) | -0.64 (0.100) | -0.12 (0.163) | -0.74 (0.172) | -0.74 (0.158) |
| High CRP subgroup (>9 mg/L) | ||||||
| N | 53 | 60 | 71 | 61 | 50 | 49 |
| DAS28 | -1.2 (0.15) | -2.3 (0.19) | -2.5 (0.15) | -1.0 (0.17) | -2.0 (0.19) | -2.3 (0.19) |
| CDAI | -15.6 (2.04) | -23.8 (2.08) | -25.5 (1.67) | -11.7 (1.94) | -23.3 (2.38) | -24.1 (2.12) |
| HAQ-DI | -0.49 (0.080) | -0.61 (0.087) | -0.78 (0.076) | -0.25 (0.074) | 0.65 (0.081) | -0.74 (0.086) |
| ACR20 by subgroup, n (%) | ||||||
| Low CRP | 15 (45%) | 19 (76%) | 10 (67%) | 2 (18%) | 13 (65%) | 16 (80%) |
| High CRP | 23 (43%) | 35 (58%) | 49 (69%) | 19 (31%) | 33 (66%) | 34 (69%) |